Filtered By:
Source: Circulation: Cardiovascular Quality and Outcomes
Condition: Heart Attack
Management: Healthcare Costs

This page shows you your search results in order of date.

Order by Relevance | Date

Total 5 results found since Jan 2013.

Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome Original Articles
Conclusions: Generic clopidogrel was noninferior to Plavix with respect to the composite end point of death and recurrent hospitalization for ACS at 1 year among adults >65 years after an ACS hospitalization. Our findings support generic clopidogrel in ACS, which could lead to substantial healthcare cost savings.
Source: Circulation: Cardiovascular Quality and Outcomes - March 13, 2018 Category: Cardiology Authors: Ko, D. T., Krumholz, H. M., Tu, J. V., Austin, P. C., Stukel, T. A., Koh, M., Chong, A., de Melo, J. F., Jackevicius, C. A. Tags: Health Services, Mortality/Survival Original Articles Source Type: research

Abstract 146: Clinical and Economic Consequences of Statin Intolerance in the U.S.: Results from an Integrated Health System Session Title: Poster Session I
Conclusion: While the majority of SI patients were on a statin, SI patients demonstrate a higher risk of some cardiovascular events; incur higher healthcare costs; and difficulty reaching LDL-C goals compared to patients without SI. Alternative treatment strategies are needed to better serve this at-risk patient population.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Sanchez, R. J., Graham, J. H., Evans, M. A., Mallya, U. G., Panaccio, M. P., Steinhubl, S. R. Tags: Session Title: Poster Session I Source Type: research

Abstract 250: Real-world Rates and Costs of Heart Failure Events Among Patients with Hyperlipidemia Session Title: Poster Session II
Conclusions: The rate and recurrence of heart failure among hyperlipidemic patients is very high and the long term healthcare costs substantial in this real-world 2-year study.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Fox, K. M., Punekar, R. S., Richhariya, A., Fisher, M. D., Gandra, S. R., Cziraky, M. J., Toth, P. P. Tags: Session Title: Poster Session II Source Type: research

Abstract 250: Economic Burden of Mortality and Cardiovascular Events among Patients with Acute Coronary Syndromes in a Commercial Health Plan Poster Session III
Conclusion: Our findings suggest that a modest 10% increase in anticoagulant use among patients with ACS would reduce mortality, MI, ST and related healthcare costs by 4%, 0.7%, and 3%, respectively. Addition of anticoagulation therapy potentially reduces the incidence of ACS-related mortality, MI, ST and associated healthcare costs to a commercial health plan, and benefits from anticoagulation use should be balanced against the risk of bleeding.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Ogden, K., Patel, A. A., Mody, S. H., Veerman, M., Crivera, C., Quock, T. P. Tags: Poster Session III Source Type: research

Abstract 251: Risk Factors for Recurrence of Cardiovascular Events Following Acute Coronary Syndrome: Longitudinal Analysis from 2006-2011 Poster Session III
Conclusion: Following an ACS event, patients with pre-admission statin use or a prior CABG had decreased risk, while older patients or those with baseline comorbidities had increased risk of an adverse CV event occurring sooner. Ultimately, identifying high-risk ACS subgroups may facilitate tailored and more aggressive treatment to improve outcomes.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Reddy, V. S., Luthra, R., Xu, Y., Wilhelm, K., Power, T. P., Fisher, M. D., Cziraky, M. J. Tags: Poster Session III Source Type: research